MA56208A - Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase - Google Patents

Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase

Info

Publication number: MA56208A
Authority: MA; Morocco
Prior art keywords: pyrazole; compounds used; disubstituted compounds; ketohexokinase inhibitors; ketohexokinase
Prior art date: 2019-06-17

Application number

MA056208A

Other languages

English (en)

Inventor

David Andrew Coates

Timothy Barrett Durham

Richard Duane Johnston

Steven Marc Massey

Patrick Gianpietro Spinazze

Douglas Richard Stack

James Lee Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-06-17

Filing date

2020-06-16

Publication date

2022-04-20

2020-06-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2022-04-20 Publication of MA56208A publication Critical patent/MA56208A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA056208A 2019-06-17 2020-06-16 Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase MA56208A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201962862382P	2019-06-17	2019-06-17
US202062975887P	2020-02-13	2020-02-13

Publications (1)

Publication Number	Publication Date
MA56208A true MA56208A (fr)	2022-04-20

Family

ID=71950812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA056208A MA56208A (fr)	2019-06-17	2020-06-16	Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase

Country Status (22)

Country	Link
US (2)	US11124500B2 (fr)
EP (1)	EP3983404B1 (fr)
JP (2)	JP6986653B2 (fr)
KR (1)	KR20220008882A (fr)
CN (1)	CN114008036A (fr)
AU (1)	AU2020295979A1 (fr)
BR (1)	BR112021023153A2 (fr)
CA (1)	CA3143490C (fr)
CL (1)	CL2021003342A1 (fr)
CO (1)	CO2021016870A2 (fr)
CR (1)	CR20210600A (fr)
EC (1)	ECSP21091203A (fr)
ES (1)	ES2961283T3 (fr)
IL (1)	IL288350A (fr)
JO (1)	JOP20210329A1 (fr)
MA (1)	MA56208A (fr)
MX (1)	MX2021015325A (fr)
PE (1)	PE20220377A1 (fr)
TW (1)	TWI750685B (fr)
UA (1)	UA126847C2 (fr)
WO (1)	WO2020257171A1 (fr)
ZA (1)	ZA202109067B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114846008B (zh) *	2019-12-25	2024-05-28	杭州中美华东制药有限公司	具有果糖激酶(khk)抑制作用的嘧啶类化合物
CN114181198A (zh) *	2020-09-15	2022-03-15	山东轩竹医药科技有限公司	嘧啶衍生物类己酮糖激酶抑制剂及其用途
WO2022135390A1 (fr) *	2020-12-25	2022-06-30	四川海思科制药有限公司	Inhibiteur de cétohexokinase et son utilisation
EP4313967A1 (fr)	2021-03-29	2024-02-07	Gilead Sciences, Inc.	Inhibiteurs de khk
TWI833193B (zh) *	2021-04-01	2024-02-21	南韓商Ｌｇ化學股份有限公司	二唑化合物及含彼的藥學組成物
KR20230098069A (ko) *	2021-12-24	2023-07-03	주식회사 엘지화학	(s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물
WO2024216034A1 (fr) *	2023-04-12	2024-10-17	Centennial Therapeutics, Llc	Composés de pyrimidine disubstitués pour l'inhibition de la cétohexokinase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101111247B1 (ko) *	2009-07-17	2012-06-12	한국과학기술연구원	Ｒｏｓ 카이네이즈 저해활성을 갖는 피라졸 화합물
WO2017075367A1 (fr) *	2015-10-28	2017-05-04	Northwestern University	Composés n-hétérocycliques aromatiques substitués en tant qu'inhibiteurs de protéine kinase activée par mitogène interagissant avec la kinase 1 (mnk1) et la kinase 2 (mnk2)
US9809579B2 (en) *	2015-12-29	2017-11-07	Pfizer Inc.	Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物

2020
- 2020-06-03 TW TW109118557A patent/TWI750685B/zh active
- 2020-06-16 CA CA3143490A patent/CA3143490C/fr active Active
- 2020-06-16 MA MA056208A patent/MA56208A/fr unknown
- 2020-06-16 CR CR20210600A patent/CR20210600A/es unknown
- 2020-06-16 EP EP20751803.6A patent/EP3983404B1/fr active Active
- 2020-06-16 WO PCT/US2020/037894 patent/WO2020257171A1/fr active Application Filing
- 2020-06-16 ES ES20751803T patent/ES2961283T3/es active Active
- 2020-06-16 PE PE2021001989A patent/PE20220377A1/es unknown
- 2020-06-16 CN CN202080044683.4A patent/CN114008036A/zh active Pending
- 2020-06-16 JP JP2021510724A patent/JP6986653B2/ja active Active
- 2020-06-16 UA UAA202106634A patent/UA126847C2/uk unknown
- 2020-06-16 MX MX2021015325A patent/MX2021015325A/es unknown
- 2020-06-16 BR BR112021023153A patent/BR112021023153A2/pt not_active Application Discontinuation
- 2020-06-16 AU AU2020295979A patent/AU2020295979A1/en not_active Abandoned
- 2020-06-16 JO JOP/2021/0329A patent/JOP20210329A1/ar unknown
- 2020-06-16 US US16/902,806 patent/US11124500B2/en active Active
- 2020-06-16 KR KR1020217040905A patent/KR20220008882A/ko not_active Application Discontinuation
2021
- 2021-09-17 US US17/478,080 patent/US11999722B2/en active Active
- 2021-11-15 ZA ZA2021/09067A patent/ZA202109067B/en unknown
- 2021-11-24 IL IL288350A patent/IL288350A/en unknown
- 2021-11-29 JP JP2021192979A patent/JP7221367B2/ja active Active
- 2021-12-13 CO CONC2021/0016870A patent/CO2021016870A2/es unknown
- 2021-12-14 CL CL2021003342A patent/CL2021003342A1/es unknown
- 2021-12-17 EC ECSENADI202191203A patent/ECSP21091203A/es unknown

Also Published As

Publication number	Publication date
US11124500B2 (en)	2021-09-21
TW202112768A (zh)	2021-04-01
EP3983404A1 (fr)	2022-04-20
JOP20210329A1 (ar)	2023-01-30
ES2961283T3 (es)	2024-03-11
UA126847C2 (uk)	2023-02-08
US20220017496A1 (en)	2022-01-20
EP3983404B1 (fr)	2023-08-09
CA3143490A1 (fr)	2020-12-24
CL2021003342A1 (es)	2022-09-09
KR20220008882A (ko)	2022-01-21
US20200392118A1 (en)	2020-12-17
CO2021016870A2 (es)	2022-01-17
IL288350A (en)	2022-01-01
PE20220377A1 (es)	2022-03-16
CA3143490C (fr)	2024-03-05
AU2020295979A1 (en)	2021-12-09
ZA202109067B (en)	2023-06-28
WO2020257171A1 (fr)	2020-12-24
JP2022031816A (ja)	2022-02-22
JP6986653B2 (ja)	2021-12-22
BR112021023153A2 (pt)	2022-01-04
US11999722B2 (en)	2024-06-04
ECSP21091203A (es)	2022-01-31
TWI750685B (zh)	2021-12-21
MX2021015325A (es)	2022-01-18
CR20210600A (es)	2022-01-11
JP2021525793A (ja)	2021-09-27
CN114008036A (zh)	2022-02-01
JP7221367B2 (ja)	2023-02-13

Publication	Publication Date	Title
MA56208A (fr)	2022-04-20	Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase
MA51610A (fr)	2021-04-21	Dérivés d'imidazole fusionnés utilisés en tant qu'inhibiteurs d'il-17
MA52486A (fr)	2021-03-10	Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA54076A (fr)	2022-02-09	2-amino-n-hétéroaryl-nicotinamides utilisés en tant qu'inhibiteurs de nav1.8
MA56398A (fr)	2022-05-04	Composés 2,3-dihydroquinazoline en tant qu'inhibiteurs de nav1.8
MA54169A (fr)	2022-02-16	Tolyles substitués utilisés en tant que fongicides
MA51846A (fr)	2021-04-21	Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
MA49566A (fr)	2020-05-20	Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA52189A (fr)	2021-02-17	Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
MA51438A (fr)	2021-04-14	Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA49888A (fr)	2020-06-24	Composés macrocycliques utilisés en tant qu'inhibiteurs de kinase ros1
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA53172A (fr)	2021-05-26	Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA47013A (fr)	2018-08-29	Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
MA53220A (fr)	2021-11-17	Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
MA46196A (fr)	2021-05-19	Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA51429A (fr)	2021-04-07	Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA51327A (fr)	2021-05-26	Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MA45375A (fr)	2019-04-24	Composés hétérocycliques utilisés en tant qu'agents antibacteriens
MA47099A (fr)	2021-05-12	Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA54378A (fr)	2022-03-09	Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA52942A (fr)	2021-04-28	Composés inhibiteurs d'oga
MA43862A (fr)	2021-06-02	Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock